91 related articles for article (PubMed ID: 38542198)
1. Recent advances in the development of celecoxib analogs as anticancer agents: A review.
Abdelhaleem EF; Kassab AE; El-Nassan HB; Khalil OM
Arch Pharm (Weinheim); 2022 Dec; 355(12):e2200326. PubMed ID: 35996360
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.
Antoniou K; Malamas M; Drosos AA
Expert Opin Pharmacother; 2007 Aug; 8(11):1719-32. PubMed ID: 17685888
[TBL] [Abstract][Full Text] [Related]
3. Repurposed Drugs Celecoxib and Fmoc-L-Leucine Alone and in Combination as Temozolomide-Resistant Antiglioma Agents-Comparative Studies on Normal and Immortalized Cell Lines, and on
Uram Ł; Pieńkowska N; Misiorek M; Szymaszek Ż; Twardowska M; Siorek M; Wołowiec S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542198
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARγ Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts, Immortalized Keratinocytes and Glioma Cells in Vitro.
Uram Ł; Misiorek M; Pichla M; Filipowicz-Rachwał A; Markowicz J; Wołowiec S; Wałajtys-Rode E
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652556
[TBL] [Abstract][Full Text] [Related]
5. Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines.
Uram Ł; Filipowicz A; Misiorek M; Pieńkowska N; Markowicz J; Wałajtys-Rode E; Wołowiec S
Eur J Pharm Sci; 2018 Nov; 124():1-9. PubMed ID: 30118847
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E
Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261
[TBL] [Abstract][Full Text] [Related]
7. Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
Ramer R; Walther U; Borchert P; Laufer S; Linnebacher M; Hinz B
J Lipid Res; 2013 Nov; 54(11):3116-29. PubMed ID: 23943857
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Badawi AF; Eldeen MB; Liu Y; Ross EA; Badr MZ
Cancer Res; 2004 Feb; 64(3):1181-9. PubMed ID: 14871855
[TBL] [Abstract][Full Text] [Related]
9. A two-pronged approach against glioblastoma: drug repurposing and nanoformulation design for in situ-controlled release.
Mendes M; Branco F; Vitorino R; Sousa J; Pais A; Vitorino C
Drug Deliv Transl Res; 2023 Dec; 13(12):3169-3191. PubMed ID: 37574500
[TBL] [Abstract][Full Text] [Related]
10. Chronic Inflammation's Transformation to Cancer: A Nanotherapeutic Paradigm.
Sohrab SS; Raj R; Nagar A; Hawthorne S; Paiva-Santos AC; Kamal MA; El-Daly MM; Azhar EI; Sharma A
Molecules; 2023 May; 28(11):. PubMed ID: 37298889
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic effects of the COX-2/PGE2 axis in the glioblastoma tumor microenvironment.
Dean PT; Hooks SB
Front Oncol; 2022; 12():1116014. PubMed ID: 36776369
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.
Pineda E; Domenech M; Hernández A; Comas S; Balaña C
Onco Targets Ther; 2023; 16():71-86. PubMed ID: 36721854
[TBL] [Abstract][Full Text] [Related]
13. Potential Therapeutic Effects of Thiazolidinedione on Malignant Glioma.
Sheu ML; Pan LY; Hu HY; Su HL; Sheehan J; Tsou HK; Pan HC
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362294
[TBL] [Abstract][Full Text] [Related]
14. PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer.
Ballav S; Biswas B; Sahu VK; Ranjan A; Basu S
Cells; 2022 Oct; 11(20):. PubMed ID: 36291082
[TBL] [Abstract][Full Text] [Related]
15. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
Ostrom QT; Price M; Neff C; Cioffi G; Waite KA; Kruchko C; Barnholtz-Sloan JS
Neuro Oncol; 2022 Oct; 24(Suppl 5):v1-v95. PubMed ID: 36196752
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
